Global burden of corpus uteri cancer in 2022 and projections to 2050: a population-based study
Corpus uteri cancer is one of the most common gynecological malignancies. We aimed to quantify the global burden of corpus uteri cancer in 2022 and project its future burden to 2050. We extracted data on cancer of the corpus uteri (ICD-10 C54) from the GLOBOCAN 2022 database, including 185 countries or territories. Age-standardized incidence and mortality rates were assessed across countries, 20 United Nations-defined world regions, and four-tier levels of the Human Development Index (HDI), with additional analyses stratified by age group. The numbers of new cases and deaths in 2050 were projected based on population growth and ageing, assuming unchanged age-specific incidence and mortality rates. In 2022, there were an estimated 420,368 new cases and 97,723 deaths from corpus uteri cancer worldwide, with age-standardized incidence and mortality rates of 8.4 and 1.7 per 100,000 women-years, respectively. Corpus uteri cancer incidence rates varied substantially across world regions, with a more than nine times difference. Mortality rates were less than four per 100,000 women-years in most countries and regions. Estimated incidence and mortality rates were generally higher in countries with higher HDI levels and among women aged ≥50 years. By 2050, the global burden of corpus uteri cancer is projected to increase to 676,296 new cases and 183,093 deaths, with the majority occurring in high and very high HDI countries. This epidemiological assessment highlights substantial geographical and socioeconomic disparities in the global burden of corpus uteri cancer. The projected increases in the numbers of new cases and deaths by 2050 underscore the need for targeted cancer control strategies to address the growing public health burden.
Authors
- Zhen Chen (ORCID: https://orcid.org/0000-0003-3355-3464)
- Xiaoyu Yin (ORCID: https://orcid.org/0009-0003-1443-2699)
- Yuehan Gao (ORCID: https://orcid.org/0009-0006-6414-315X)
- Zixuan Su (ORCID: https://orcid.org/0009-0008-2513-7341)
- Aijun Yin (ORCID: https://orcid.org/0000-0003-4159-5146)
- Zhuang Li (ORCID: https://orcid.org/0000-0001-6855-2803)
- Yu Chen (ORCID: https://orcid.org/0009-0006-2371-5203)
- Changjian Qi (ORCID: https://orcid.org/0009-0008-2755-1386)
- Beihua Kong
- Haocheng Zhang (ORCID: https://orcid.org/0009-0002-0690-0600)
- Jiayue Ding
Institutions
- Shandong University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s12885-026-17376-2
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China